Key result
Baseline severity of depressive symptoms (MADRS score) independently predicted sustained virological response in patients treated for chronic HCV (OR 0.88; 95% CI 0.80-0.98; p=0.013).
Why the study?
The study aimed to evaluate baseline predictors of sustained virological response in patients treated with PEG-IFN-α/RBV for chronic HCV infection.
Does the severity of baseline depressive symptoms predict sustained virological response in patients with chronic HCV infection treated with pegylated interferon-α and ribavirin?
Cohort (n=101)
Does the severity of baseline depressive symptoms predict sustained virological response in patients with chronic HCV infection treated with pegylated interferon-α and ribavirin?
Odds Ratio: 0.88 (95% CI 0.8–0.98)
p-value: p=.013
The severity of depressive symptoms before treatment is an independent predictor of sustained virological response in patients treated for chronic HCV infection.
Higher baseline depressive symptoms were associated with lower SVR; leaves open whether treating depression improves HCV treatment outcomes.
BACKGROUND: Sustained virological response (SVR) is the best indicator of successful therapy for hepatitis C virus (HCV) infection. Patients with chronic HCV infection treated with pegylated interferon-α and ribavirin (PEG-IFN-α/RBV) can achieve SVR 56% of the time. OBJECTIVES: This study aimed to evaluate baseline predictors of SVR in patients treated with PEG-IFN-α/RBV for HCV chronic infection. METHODS: A total of 101 patients receiving PEG-IFN-α/RBV for chronic HCV infection participated in the prospective cohort study. Symptoms of depression were assessed with the Montgomery-Åsberg Depression Rating Scale (MADRS) before the treatment. The multivariate regression analysis was applied to determine predictors of SVR. RESULTS: Of a total of 101 patients included, 99 patients reached the primary end point-24 weeks after completing treatment. After the initial analysis of probable predictive variables, the logistic analysis included age, sex, HCV genetic type, and MADRS score. The HCV genotype (odds ratio = 0.22 [confidence interval = 0.073-0.68, p = .008) and MADRS score (OR = 0.88 [confidence interval = 0.80-0.98), p = .013]) predicted an SVR outcome. CONCLUSIONS: The severity of depressive symptoms before treatment and HCV genotype are independent predictors of SVR.
No takes yet. Share an insight, caveat, or question.
Pawłowski et al. (2024) conducted a cohort in chronic HCV infection (n=101). Severity of depressive symptoms (MADRS score) was evaluated on Sustained virological response (SVR) (OR 0.88, 95% CI 0.80-0.98, p=.013). Baseline severity of depressive symptoms (MADRS score) independently predicted sustained virological response in patients treated for chronic HCV (OR 0.88; 95% CI 0.80-0.98; p=0.013).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: